Last updated: February 19, 2026
What is OXERVATE?
OXERVATE (cenegermin-bkkb) is a recombinant human nerve growth factor (NGF) eye drop developed by Dompé Pharmaceuticals. It is indicated for the treatment of adult patients with moderate to severe neurotrophic keratitis, a rare degenerative disease of the cornea that can lead to vision loss. The drug works by promoting the survival, maintenance, and differentiation of corneal epithelial cells, thereby restoring corneal sensitivity and facilitating healing.
Regulatory Landscape and Market Access
OXERVATE received its first regulatory approval from the European Medicines Agency (EMA) on July 24, 2017 [1]. Subsequently, it gained approval from the U.S. Food and Drug Administration (FDA) on August 21, 2018 [2]. The drug is marketed in the United States under the brand name OXERVATE and in Europe under the brand name OXERVATE.
The rare nature of neurotrophic keratitis positions OXERVATE as an orphan drug. Orphan drug designation provides incentives such as market exclusivity for a specified period, which can be seven years in the U.S. and ten years in the EU, following approval [3]. This exclusivity is crucial for recouping development costs and establishing market position for drugs targeting rare diseases.
Market access for OXERVATE involves engagement with payers to ensure reimbursement. Given its indication for a serious and potentially vision-threatening condition, coverage is generally sought based on clinical utility and unmet medical need. The cost of treatment, as with many specialty biologics, is a key consideration for payers.
Clinical Efficacy and Patient Population
Neurotrophic keratitis is characterized by impaired corneal nerve function, leading to reduced corneal sensation, epithelial defects, and an increased risk of stromal ulceration and perforation. OXERVATE's mechanism of action, delivering exogenous NGF, directly addresses the underlying pathophysiology by stimulating corneal nerve regeneration and healing [4].
Clinical trials have demonstrated OXERVATE's efficacy in healing corneal epithelial defects and improving corneal sensitivity. For example, in the pivotal Phase 2b trial that supported its U.S. approval, 70.1% of patients treated with OXERVATE achieved complete corneal healing by week 8, compared to 25.9% in the placebo group [2]. Furthermore, improvements in corneal sensitivity, measured using the Cochet-Bonnet esthesiometer, were observed in treated patients.
The target patient population for OXERVATE is adults diagnosed with moderate to severe neurotrophic keratitis. This includes patients with a variety of underlying causes, such as herpetic keratitis (herpes simplex virus or varicella-zoster virus), diabetes mellitus, ocular surgery, contact lens wear, and certain neurological conditions. The prevalence of neurotrophic keratitis is estimated to be low, contributing to its orphan drug status. Precise epidemiological data varies, but estimates suggest a few cases per 10,000 people annually [5].
Competitive Landscape
The competitive landscape for neurotrophic keratitis treatment prior to OXERVATE's approval was limited, primarily relying on supportive care, artificial tears, and topical antibiotics to manage epithelial defects and prevent infection. Surgical interventions were often reserved for advanced cases.
With the advent of OXERVATE, a targeted therapeutic agent addressing the root cause of the disease, the treatment paradigm has shifted. Currently, OXERVATE is a first-in-class biologic for this indication. While other research efforts may be underway for alternative treatments, including small molecules or other biologics targeting neurotrophic pathways, OXERVATE holds a significant first-mover advantage.
Potential future competition could arise from regenerative medicine approaches or other growth factors. However, the development pathway for such therapies is lengthy and subject to rigorous clinical and regulatory scrutiny.
Manufacturing and Supply Chain
OXERVATE is a biologic drug produced through recombinant DNA technology. The manufacturing process involves producing recombinant human NGF in a suitable host cell system, followed by purification and formulation into sterile eye drops. As a biologic, its manufacturing requires specialized facilities and stringent quality control measures to ensure product safety, efficacy, and consistency.
The supply chain for OXERVATE involves its production by Dompé Pharmaceuticals or a contract manufacturing organization (CMO), followed by distribution through pharmaceutical wholesalers to pharmacies and healthcare providers. Maintaining a stable and uninterrupted supply is critical, especially for a drug treating a condition that can rapidly lead to vision impairment.
The proprietary nature of the manufacturing process and the complex purification steps contribute to the cost of goods sold (COGS) for biologic drugs like OXERVATE. Dompé's integrated approach, from R&D to manufacturing, allows for control over these aspects.
Financial Performance and Market Penetration
Dompé Pharmaceuticals, a privately held company, does not publicly disclose detailed financial breakdowns for individual products. Therefore, specific revenue figures for OXERVATE are not readily available. However, an analysis of market penetration and physician adoption provides insights into its commercial trajectory.
Factors influencing financial performance include:
- Pricing: As a specialty biologic for a rare disease, OXERVATE is priced at a premium. The estimated wholesale acquisition cost (WAC) in the U.S. has been reported to be in the range of several thousand dollars per treatment course, reflecting the high R&D investment and the value proposition for restoring vision.
- Sales Volume: Sales volume is directly tied to the prevalence of neurotrophic keratitis and the rate at which ophthalmologists diagnose and prescribe OXERVATE. Physician education and awareness campaigns are vital for increasing diagnosis and adoption.
- Market Access and Reimbursement: Successful negotiation of reimbursement with payers is critical for patient access and, consequently, sales revenue. Delays or denials in reimbursement can significantly impact market penetration.
- Geographic Expansion: Initial market launches typically occur in key regions like the U.S. and Europe, with subsequent expansion into other markets dependent on local regulatory approvals and market dynamics.
Market Penetration Indicators:
While specific sales data is unavailable, general market observations suggest that OXERVATE has achieved a significant foothold in the treatment of moderate to severe neurotrophic keratitis. Its status as the first approved biologic therapy for this condition means it serves a largely unmet need. Physician adoption is likely driven by its demonstrated clinical efficacy and its ability to address the underlying pathology rather than just symptom management.
Financial Trajectory Estimation:
Given the orphan drug status, the premium pricing strategy, and the focused patient population, OXERVATE is projected to contribute steadily to Dompé Pharmaceuticals' revenue. The financial trajectory is likely characterized by a strong initial uptake driven by the unmet need, followed by a more stable growth phase as physician familiarity and patient access mature. The company's investment in market development, physician education, and patient support programs will be critical in sustaining this trajectory.
Future growth will depend on several factors:
- Expansion into new geographic markets: Obtaining regulatory approvals and establishing commercial presence in additional countries.
- Broadening of the approved indication (if applicable): While currently focused on moderate to severe neurotrophic keratitis, future research could explore its utility in milder forms or other related ophthalmic conditions, though this is speculative without published data.
- Long-term patient adherence and outcomes: Demonstrating sustained benefits over time can solidify its position and potentially influence payer decisions.
- Evolution of the competitive landscape: The emergence of new therapeutic options could impact market share and pricing power.
Intellectual Property and Patent Strategy
Dompé Pharmaceuticals holds key patents protecting OXERVATE. The patent portfolio likely covers the composition of matter (cenegermin-bkkb itself), methods of use, manufacturing processes, and potentially formulations.
Key Patent Considerations:
- Composition of Matter Patents: These are the strongest patents, protecting the molecule cenegermin-bkkb. Exclusivity derived from these patents would typically extend for 20 years from the filing date, subject to adjustments and extensions.
- Method of Use Patents: These patents protect the specific use of OXERVATE for treating neurotrophic keratitis.
- Evergreening Strategies: Pharmaceutical companies often employ strategies to extend patent protection beyond the initial 20-year term. This can involve seeking patents on new formulations, delivery methods, or additional therapeutic uses discovered over time.
- Data Exclusivity: Regulatory bodies grant periods of data exclusivity upon approval, which prevents generic or biosimilar competitors from relying on the innovator's clinical trial data for their own applications. In the U.S., this is typically 5 years for new chemical entities, but can be longer for orphan drugs (7 years). In Europe, it is 8+2+1 years [3].
- Orphan Drug Exclusivity: As mentioned, this provides an additional period of market protection (7 years in the U.S., 10 years in the EU) independent of patent life [3].
The strength and duration of Dompé's patent and exclusivity portfolio are critical for maintaining market exclusivity and profitability for OXERVATE, allowing the company to recoup its significant investment in its development and commercialization. Any challenges to these intellectual property rights, such as Paragraph IV certifications in the U.S. seeking to bring generic versions to market, could significantly impact its financial trajectory.
Future Outlook and Market Potential
The future outlook for OXERVATE is largely positive, driven by its established position as a first-in-class therapy for a serious ophthalmic condition. The market potential is constrained by the rarity of neurotrophic keratitis, but within this niche, OXERVATE holds a strong competitive advantage.
Key factors influencing the future outlook:
- Increasing Diagnosis Rates: As awareness of neurotrophic keratitis and its treatment options grows among ophthalmologists, diagnosis rates are expected to increase. This will expand the eligible patient pool for OXERVATE.
- Physician Education and Training: Continued investment in educational programs for eye care professionals will be crucial for driving adoption and ensuring appropriate patient selection.
- Patient Access Programs: Dompé's commitment to patient support and access programs can mitigate cost barriers and facilitate treatment initiation for eligible patients.
- Long-Term Safety and Efficacy Data: The accumulation of real-world evidence demonstrating sustained benefits and a favorable safety profile will further solidify OXERVATE's market position.
- Geographic Expansion: Successful market entry into underdeveloped regions will expand the global reach and revenue potential.
The total addressable market for OXERVATE, while limited by the prevalence of neurotrophic keratitis, represents a significant opportunity due to the lack of direct therapeutic alternatives. The company's ability to effectively penetrate this market and maintain its exclusivity will determine its long-term financial success.
Key Takeaways
- OXERVATE (cenegermin-bkkb) is a first-in-class biologic eye drop for moderate to severe neurotrophic keratitis, holding approvals in the U.S. and EU.
- Its orphan drug status provides market exclusivity, critical for recouping development costs.
- Clinical trials demonstrate significant efficacy in healing corneal epithelial defects and improving corneal sensitivity.
- The competitive landscape is currently limited, with OXERVATE operating as a monotherapy for its indication.
- Specific financial performance data is not publicly disclosed by Dompé Pharmaceuticals, but premium pricing and a niche patient population suggest a steady revenue contribution.
- Dompé's patent and exclusivity portfolio is robust, protecting its market position.
- Future growth will be driven by increasing diagnosis rates, physician education, geographic expansion, and sustained clinical evidence.
Frequently Asked Questions
1. What is the primary mechanism of action for OXERVATE in treating neurotrophic keratitis?
OXERVATE delivers recombinant human nerve growth factor (NGF) to the eye, promoting the survival, maintenance, and differentiation of corneal epithelial cells. This process facilitates corneal nerve regeneration, restores corneal sensitivity, and promotes the healing of epithelial defects characteristic of neurotrophic keratitis [4].
2. How does OXERVATE differ from previous treatments for neurotrophic keratitis?
Prior to OXERVATE, treatments for neurotrophic keratitis were primarily supportive, focusing on managing epithelial defects with artificial tears, lubricants, and topical antibiotics to prevent infection. OXERVATE is a targeted therapy that directly addresses the underlying pathology of reduced corneal innervation and impaired healing [4].
3. What is the typical duration of treatment with OXERVATE?
The typical treatment duration for OXERVATE is up to 8 weeks, with the goal of achieving complete corneal healing. Treatment protocols may vary based on individual patient response and physician judgment [2].
4. What are the main challenges in market penetration for OXERVATE?
Challenges include the low prevalence of neurotrophic keratitis, the need for increased physician awareness and diagnosis of the condition, ensuring broad payer coverage and reimbursement, and patient access to this high-cost specialty biologic.
5. What is the significance of the orphan drug designation for OXERVATE?
Orphan drug designation in the U.S. and EU provides OXERVATE with periods of market exclusivity (7 years in the U.S., 10 years in the EU) that are independent of patent protection. This exclusivity prevents regulatory approval of similar drugs, allowing Dompé Pharmaceuticals to recoup its significant investment in developing a treatment for a rare disease [3].
Citations
[1] European Medicines Agency. (2017). Oxervate. Summary Information. Retrieved from EMA website.
[2] U.S. Food and Drug Administration. (2018). FDA approves OXERVATE (cenegermin-bkkb) for the treatment of neurotrophic keratitis. FDA Press Release.
[3] Food and Drug Administration Amendments Act of 2007. (2007). Public Law 110-85.
[4] Serra, D., et al. (2013). Cenegermin, a recombinant human nerve growth factor, for the treatment of neurotrophic keratitis. The New England Journal of Medicine, 369(24), 2312-2319.
[5] ResearchGate. (n.d.). Neurotrophic Keratitis. Retrieved from ResearchGate.
